摘要
目的研究重组人血管内皮抑制素联合顺铂行心包内灌注治疗非小细胞肺癌的疗效。方法选取非小细胞肺癌伴恶性心包积液患者77例,随机分为3组重组人血管内皮抑制素(恩度)组(n=26)、顺铂组(n=24)、恩度+顺铂组(n=27),3组患者均行心包穿刺并留置中心静脉导管于心包腔内,按分组分别向心包内灌注重组人血管内皮抑制素(恩度)单药、顺铂单药及重组人血管内皮抑制素(恩度)+顺铂。观察3组疗效及不良反应发生情况。结果恩度组、顺铂组、恩度+顺铂组治疗非小细胞肺癌引起的恶性心包积液,组间差异均有统计学意义(P<0.05);有效率依次升高,且恩度组、恩度+顺铂组不良反应发生率均低于顺铂组(P<0.05),而恩度组与恩度+顺铂组比较,差异无统计学意义(P>0.05)。结论恩度联合顺铂心包灌注非小细胞肺癌恶性心包积液疗效好,且不良反应发生率低。
Objective To observe the efficacy of recombinant human endostatin combined with pericardial perfusion of cisplatin on non-small cell lung cancer (NSCLC)patients with malignant pericardial effusion(MPCE).Methods A total of 77 NSCLC patients with MPCE were randomly divided into recombinant human endostatin group(trade name:Endostar;n=26),cisplatin group(n=24)and Endostar +cisplatin group(n=27).All patients in the three groups were managed by would be underwent pericardiocentesis with a central venous catheteRindwelled in the pericardial cavity.They were intrapericardially perfused with recombinant human endostatin,cisplatin and their combination in the three groups,respectively.The efficacy and adverse events were compared among the three groups.Results There was a significant difference in the efficacy of recombinant human endostatin,cisplatin and their combination on NSCLC patients with MPCE(P<0.05),which gradually increased in the three groups.The incidence of adverse events in the Endostar group and Endostar +cisplatin group was significantly lower than that of cisplatin group(P<0.05),which was comparable between the formeRtwo groups(P>0.05).Conclusion Recombinant human endostatin combined with pericardial perfusion of cisplatin has a good efficacy on NSCLC patients with MPCE,with a low incidence of adverse events.
作者
刘世伟
杨璞
李反念
豆瑞刚
曹万乐
李玉坤
王建勋
朱梓铭
刘扬
高计林
刘月焜
LIU Shiwei;YANG Pu;LI Fannian(Department of Thoracic Surgery,First Affiliated Hospital of Xingtai Medical College(The First Hospital of Xingtai),Hebei,Xingtai 054001,China)
出处
《河北医药》
CAS
2024年第2期201-204,209,共5页
Hebei Medical Journal
基金
河北省医学科学研究重点课题计划(编号:20220444)。
